Zogenix: New data on Zogenix's ZX008 to be presented at AES meeting
Zogenix announced the presentation of four clinical and scientific posters, and the hosting of a scientific exhibit room at the 70th Annual American Epilepsy Society meeting, which will take place at the George R. Brown Convention Center in Houston, Texas, from December 2 - 6, 2016. Four posters highlighting the results of investigator initiated studies will be available in the main exhibitor hall of the congress. One poster will highlight the interim results for patients who have completed at least 8 weeks of treatment in a Phase 2 study of ZX008 in Lennox Gastaut syndrome. The second poster will provide an update from the ongoing open-label prospective study of ZX008 in Dravet syndrome. A third poster will be the first to evaluate the potential protective effect of fenfluramine in an accepted pre-clinical model of Sudden Unexpected Death in Epilepsy. The fourth poster will discuss findings from roundtable discussions with parents and caregivers of children with Dravet syndrome that sought to identify those aspects of caregivers' lives that are most impacted by caring for a child with Dravet syndrome.